Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Glioma × Naltrexone × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 2 Prostatic Neoplasms 1 Overweight 1 Obesity 1 Glioma 1 Glioblastoma 1 Carcinoma, Lobular 1 Carcinoma, Intraductal, Noninfiltrating 1 Breast Carcinoma In Situ 1

Interventions

Temozolomide 56 Bevacizumab 37 Radiotherapy 19 Magnetic Resonance Spectroscopy 18 Irinotecan 15 Specimen Handling 9 Carmustine 9 Carboplatin 9 olaparib 6 X-Rays 6 Surgical Procedures, Operative 6 Phantoms, Imaging 6 Cyclophosphamide 6 Thalidomide 5 Nuclear Medicine Department, Hospital 5 Biopsy 5 trametinib 4 pembrolizumab 4 Radiation 4 Nivolumab 4 Lomustine 4 Everolimus 4 Cisplatin 4 Aminolevulinic Acid 4 sargramostim 3 poly ICLC 3 ivosidenib 3 fluorodopa F 18 3 erdafitinib 3 dabrafenib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01303835 2015-07-17

Low Dose Naltrexone for Glioma Patients

Duke University

Phase 2 Completed

110 enrolled 9 charts

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡